Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

Tian, Zhichao; Yao, Weitao

doi:10.3389/fonc.2022.815900

Cited by 18 publications

(13 citation statements)

References 131 publications

(123 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some drugs are suitable for combination with PD1/L1 inhibitor, while others are not. For example, it has been demonstrated that the use of glucocorticoids while immunotherapy will lead to poor prognosis ( 90 ). Therefore, chemotherapy drugs that need to be accompanied by glucocorticoids may not be suitable for combination with immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas

Tian

Yao

2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

There is an urgent clinical need for new therapeutic regimens for the effective treatment of advanced sarcomas. Accumulating evidence suggests that programmed death receptor-1/programmed death protein ligand-1 (PD-1/L1) inhibitors have synergistic effects with chemotherapy and have been approved for treatment of lung cancer, gastroesophageal cancer, and breast cancer. In this review, we reviewed the synergistic mechanism of PD-1/L1 inhibitors plus chemotherapy in the treatment of cancers, and the application of this combined regimen in several cancers, followed by a summary of the current evidence on the application of this combined regimen in the treatment of sarcomas as well as the main clinical trials currently underway. Based on the findings of this review, we believe that this combined approach will play an important role in the treatment of some subtypes of sarcomas in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas

Tian

Yao

2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Paclitaxel, docetaxel, and cabazitaxel are among the most widely used anticancer drugs for first-line treatments of several solid tumors [ 11 , 12 ]. The incidence of CIPN due to taxane varies from 11% to 87% [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

Emerging Approaches for the Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Therapeutic Potential of the C5a/C5aR Axis

et al. 2022

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy (CIPN) is the most common neurologic complication of chemotherapy, resulting in symptoms like pain, sensory loss, and numbness in the hands and feet that cause lots of uneasiness in patients with cancer. They often suffer from pain so severe that it interrupts the treatment, thus invalidating the entire chemotherapy-based healing process, and significantly reducing their quality of life. In this paper, we underline the role of the complement system in CIPN, highlighting the relevance of the C5a fragment and its receptor C5aR1, whose activation is thought to be involved in triggering a cascade of events that can lead to CIPN onset. Recent experimental data showed the ability of docetaxel and paclitaxel to specifically bind and activate C5aR1, thus shining light on one of the molecular mechanisms by which taxanes may activate a cascade of events leading to neuropathy. According to these new evidence, it was possible to suggest new mechanisms underlying the pathophysiology of CIPN. Hence, the C5a/C5aR1 axis may represent a new target for CIPN treatment, and the use of C5aR1 inhibitors can be proposed as a potential new therapeutic option to manage this high unmet medical need.

show abstract

“…Later advances in nanotechnology led to the development of nab-paclitaxel (Abraxane ® ), a nanoparticle albumin-bound paclitaxel, which is a new type of taxane antineoplastic drug and has been indicated for the treatment of metastatic breast cancer, non-small cell lung cancer and metastatic pancreatic cancer 201 . Evidence shows that nab-paclitaxel has promising effects in the treatment of angiosarcoma, epithelioid sarcoma, leiomyosarcoma, and other subtypes of soft tissue sarcomas 202 and can be safely combined with gemcitabine or receptor tyrosine inhibitors for an improved curative effect 203 , 204 . On the other hand, nanomedicine-immunotherapy combinations remain poorly investigated in sarcomas.…”

Section: Strategies To Overcome Barriers To Sarcoma Immunotherapymentioning

confidence: 99%

Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness

Panagi¹,

Pilavaki²,

Constantinidou³

et al. 2022

Theranostics

View full text Add to dashboard Cite

Sarcomas are uncommon malignancies of mesenchymal origin that can arise throughout the human lifespan, at any part of the body. Surgery remains the optimal treatment modality whilst response to conventional treatments, such as chemotherapy and radiation, is minimal. Immunotherapy has emerged as a novel approach to treat different cancer types but efficacy in soft tissue sarcoma and bone sarcoma is limited to distinct subtypes. Growing evidence shows that cancer-stroma cell interactions and their microenvironment play a key role in the effectiveness of immunotherapy. However, the pathophysiological and immunological properties of the sarcoma tumor microenvironment in relation to immunotherapy advances, has not been broadly reviewed. Here, we provide an up-to-date overview of the different immunotherapy modalities as potential treatments for sarcoma, identify barriers posed by the sarcoma microenvironment to immunotherapy, highlight their relevance for impeding effectiveness, and suggest mechanisms to overcome these barriers.

show abstract

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas

Cited by 18 publications

References 131 publications

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas

Emerging Approaches for the Management of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Therapeutic Potential of the C5a/C5aR Axis

Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness

Contact Info

Product

Resources

About